Ovid Therapeutics Reports Business Updates and Third Quarter 2026 Financial Results
Key Highlights
- ➤Cash, equivalents and marketable securities totaled $161.4 million at September 30, 2026
- ➤Ovid reported a third-quarter net loss of $20.8 million, or $0.10 per share
- ➤OV329 Phase 2 focal epilepsy study expected to complete in the second half of 2027
- ➤OV4071 Phase 1 topline data and ketamine challenge results expected in Q1 2027
- ➤Ovid eligible for up to $294.5 million in potential soticlestat milestone payments
Expert Statements
Meg Alexander, President and Chief Executive Officer of Ovid Therapeutics
“The third quarter was focused on execution toward multiple, near-term clinical milestones across our pipeline”
Meg Alexander, President and Chief Executive Officer of Ovid Therapeutics
“We anticipate findings from two high potential programs in early 2027, which may respectively demonstrate the broad potential of KCC2 direct activation and the anticonvulsant profile of OV329, a next-generation GABA-AT inhibitor.”
Meg Alexander, President and Chief Executive Officer of Ovid Therapeutics
“In addition to focal epilepsy, we are excited to start characterizing OV329 in specific developmental epileptic encephalopathies for which there is significant need, and the current treatments are limited.”
Meg Alexander, President and Chief Executive Officer of Ovid Therapeutics
“We intend to initiate the first DEE study in patients living with TSC before year-end.”
Meg Alexander, President and Chief Executive Officer of Ovid Therapeutics
“With strengthened clinical operations and capital to support upcoming milestones, Ovid is well positioned to deliver on our priorities and advance better, gentler medicines.”
* OV329 is advancing in a global, Phase 2 focal epilepsy study expected to read out in H2 2027 * Ovid is enrolling patients in ongoing photosensitivity study intended to demonstrate the anticonvulsant effect of OV329; results expected in early 2027 * OV4071, the first-ever oral KCC2 direct activator, continues to progress in a Phase 1 single- and multiple-ascending dose study; translational ketamine challenge study ready for initiation * Advancement of a pediatric formulation of OV329 is on track and Company plans to initiate a study in TSC-associated seizures before year-end 2026, representing the first indication in a broad potential DEE franchise * Cash, cash equivalents and marketable securities were $161.4 million as of September 30, 2026; expected financial runway into 2029 NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today provided business updates including financial results for the third quarter ended September 30, 2026.
Get started
Create a free account to read the full story.